Targeting a specific type of kidney cancer caused by gene fusions
Therapeutic targeting for translocation renal cell carcinoma
This study is looking for new treatments for a rare and tough type of kidney cancer called translocation renal cell carcinoma (tRCC) by finding small molecules that can block the harmful interactions between certain proteins that help the cancer grow.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-10944705 on NIH RePORTER |
What this research studies
This research focuses on translocation renal cell carcinoma (tRCC), a rare and aggressive form of kidney cancer that often goes misdiagnosed. The study aims to identify small molecules that can disrupt the interactions between specific proteins involved in the cancer's progression. By utilizing advanced imaging techniques, researchers will explore how these proteins interact and how they can be targeted to inhibit cancer cell growth. The goal is to develop effective therapies for patients suffering from this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with translocation renal cell carcinoma, particularly those who have not responded to existing treatments.
Not a fit: Patients with other types of kidney cancer or those without the specific gene fusions associated with tRCC may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve outcomes for patients with translocation renal cell carcinoma.
How similar studies have performed: While research on targeted therapies for tRCC is limited, preliminary studies have shown promise in targeting the protein interactions involved in this cancer type.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Pili, Roberto — State University of New York at Buffalo
- Study coordinator: Pili, Roberto
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.